Well we already have the Pediatric data . That increases confidence that the adult data should be strong ...but maybe not as good as Pediatric .. The EUPHRATES trial failed its primary end point. Thats unlikely with NEUTRALIZE-AKI due to the conservative design Dr Chung went with . I dont know anything about Spectral Med ...but note ICU has several advantages ...prior pilot trials and the Pediatric trial However I dont know if theres anything in the ICU adult trial design providing for an early stop or reducing enrollment ...or how much lea way the DSMB has on those decisions JMO Kiwi
Market Data 
Markets 
